Michael Lanuti , MD

Michael Lanuti, MD

Division of Thoracic Surgery
55 Fruit Street, BLK 1570
Boston, MA 02114
(617) 726-6751
(617) 726-7667
mlanuti@partners.org

Clinical Background

MD Degree:
University of Pennsylvania School of Medicine, 1994

Residency:
University of Pennsylvania Medical Center
Post Doctoral Fellow, Thoracic Oncology Research Laboratory, University of Pennsylvania Medical Center

Fellowship:
Massachusetts General Hospital, Boston MA
Cardiothoracic Surgery

Board Certification:
Board Certified General Surgery
Board Certified Thoracic Surgery

Clinical Interests

Thoracic oncology including lung cancer, esophageal cancer, pleural-based malignancies, palmar hyperhidrosis, chest wall deformity, benign esophageal disease, minimally invasive procedures, PET imaging of lung cancer, and radiofrequency ablation of lung nodules.

Research Interests

Translational research in thoracic oncology focusing on the development of novel gene therapy strategies for lung and esophageal cancer, development and participation in national clinical trials for resectable lung cancer, radiofrequency ablation for unresectable lung cancer, evaluation of novel noninvasive imaging for lung cancer staging.

Selected Publications

Lanuti M, de Delva PE, Maher A, Wright CD, Wain JC,  Gaissert HA,  Donahue DM,  Mathisen DJ.  Feasibility and outcomes of an early extubation policy after esophagectomy.  Ann Thorac Surg 2006; 82:2037-2041.

Miller, JC, Shepard JO, Lanuti M, Aquino S, Thrall JH and Lee SI.  Radiology utilization rounds of the Massachusetts General Hospital: Evaluating pulmonary nodules.  J Amer College Radiology, (in press)2007.

Lanuti M, de Delva PE, Wright CD, Wain JC, Donahue DM, Gaissert, HA Mathisen DJ. Post-esophagectomy gastric outlet obstruction: role of pyloromyotomy and management with endoscopic pyloric dilatation.  Eur J Cardiothorac Surg, 2007; 31(2): 145-153.

Lanuti M, Goodwin, J, Tanabe KK.  Combined oncolysis and anti-angiogenesis gene therapy using a herpes simplex virus expressing endostatin in a murine lung cancer model.  Presented at Society of Gene Therapy, Baltimore, April 2006.

Lanuti M, Rudginsky S, Force SD, Lambright ES, Chang MY, Amin KM, Kaiser LR, Scheule RM, Albelda SM.  Cationic lipid: bacterial DNA complexes elicit anti-tumor effects and adaptive immunity in murine intraperitoneal tumor models, Cancer Res 2000;60:1-9.

Sterman DH, Molnar-Kimber, Iyengar T, Chang M, Lanuti M, Amin K, Pierce B, Kang E, Treat J, Recio A, Litzky L, Wilson JM, Kaiser LR, Albelda SM.  A pilot study of systemic corticosteroid administration in conjunction with intrapleural adenoviral vector administration in patients with malignant pleural mesothelioma.  Cancer Gene Ther 2000 Dec;7(12):1511-18.

Lanuti M, Gao GP, Force SD, Chang MY, El Kouri C, Amin KM, Hughes JV, Wilson JM, Kaiser LR, Albelda SM. Evaluation of an E1E4-deleted adenovirus expressing the HSVtk suicide gene in cancer gene therapy. Hum Gene Ther 1999;10(3):463-475. 

Lanuti M, El Kouri C, Chang MY, Force SD, Amin KM, Kaiser LR, Albelda SM.  Use of protamine to augment adenoviral-mediated cancer gene therapy. Gene Therapy  1999;6(9):1600-10.